Amrutanjan Health Care LimitedQ1 FY27 Results & Financial Update
Amrutanjan Health Care Limited: Q1 FY27 standalone results and company financials – revenue ₹102.97 Cr, PAT ₹4.37 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Amrutanjan Health Care price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Amrutanjan Health Care Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Amrutanjan Health Care Limited recorded standalone revenue from operations of INR 102.97 crore for the quarter ended June 30, 2026 (Q1 FY27). Total income for the period stood at INR 106.78 crore, inclusive of other income amounting to INR 3.81 crore.
Profit before exceptional items and tax came in at INR 8.10 crore. After accounting for an exceptional item of INR 2.03 crore pertaining to additional lease rent adjustments, profit before tax (PBT) stood at INR 6.07 crore.
The company reported a net profit after tax (PAT) of INR 4.37 crore for the quarter, resulting in basic and diluted earnings per share (EPS) of INR 1.51 (not annualised).
According to company investor disclosures, gross sales for the quarter grew by approximately 9.48% year-on-year compared to Q1 FY26, driven by robust volume expansion in the women's hygiene and new product categories.
The core pain management segment experienced headwinds, recording a gross sales decline of 9% year-on-year due to a broader category slowdown, retailer inventory adjustments post-GST implementation, and high base effects from the corresponding quarter of the previous year.
Conversely, the women's hygiene brand Comfy demonstrated strong performance with gross sales expanding by 21% year-on-year, lifting its contribution to total company sales to 33% compared to 29% in the same quarter last year.
Operating margins and profitability faced downward pressures during the quarter due to higher employee benefit expenses, escalated advertising and selling expenditures to support new launches, and cost-of-goods-sold headwinds linked to geopolitical tensions in West Asia.
Management remains focused on scaling capacity utilization at its newly commissioned greenfield manufacturing plant in Telangana, expanding retail distribution touchpoints, and driving double-digit revenue and operating profit growth for the full financial year.
01 · Business model
What does Amrutanjan Health Care do?
Amrutanjan Health Care Limited is a well-established Indian consumer health and wellness enterprise founded in 1893, operating primarily in the over-the-counter (OTC) pharmaceuticals, feminine hygiene, and healthy beverage segments.
The company's core revenue engine is anchored by its flagship Pain Management portfolio under the Brand Amrutanjan, which historically contributes around 65% of total company revenue through balms, roll-ons, patches, and sprays.
Beyond traditional analgesics, the company manufactures and distributes feminine hygiene products under the Comfy brand, congestion and cold remedies under Brand Relief, and rehydration beverages through Electro+ and Enerlyte lines.
Products are distributed extensively across traditional and modern retail channels pan-India, supported by both outsourced manufacturing and in-house greenfield production facilities.
02 · Historical context
What shaped the business before this quarter
During FY 2005-06, the Government of Tamil Nadu retrospectively revised lease rents for leasehold land dating back to November 2001. Following protracted legal proceedings that culminated in the Madras High Court dismissing the company's appeal in March 2026, a provision of INR 7.61 crore was recorded in FY26, followed by a final settlement demand and supplementary provision of INR 2.03 crore in Q1 FY27.
Earlier, the company completed a major capital expenditure milestone by investing INR 150 crore to commission a greenfield sanitary napkin manufacturing plant in Telangana, representing its fifth manufacturing facility and equipped with high-speed automated lines from Japan.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹102.97 Cr |
| Total income | ₹106.78 Cr |
| Profit before tax | ₹6.07 Cr |
| Profit after tax | ₹4.37 Cr |
| EPS | ₹1.51 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Brand Comfy delivered strong gross sales growth of 21% year-on-year, led by a 43% surge in the Comfy XL variant and a 24% increase in 18-unit value packs, raising its revenue share to 33% of total company sales.
The flagship pain management segment registered a 9% year-on-year decline in gross sales (with headache and body ache lines down 10% and 9% respectively), impacted by a broader industry volume contraction of 3.4% per IQVIA data and post-GST retail purchasing friction.
The beverages segment posted an 11% overall growth rate, driven by a 13.88% increase in rehydration drinks, with Electro+ Tetra formats recording a fourfold increase over the corresponding period last year despite regulatory transitions under FSSAI.
Recent launches introduced in Q4 FY26—including Comfy Close and Clean women's razors, Amrutanjan Smoothe men's razors, and Amrutanjan Plastry wound care lines—achieved combined revenues of over INR 4 crore during Q1 FY27, contributing 4% to total company sales.
What drove margins
Management noted that raw and packing material costs remained elevated compared to Q1 FY26 due to supply chain disruptions stemming from the conflict in West Asia, partially offset by lower menthol crystal prices and targeted price increases.
Advertisement and selling expenses increased to INR 7.81 crore from INR 7.37 crore in Q1 FY26, with dedicated promotion spend for Comfy rising to INR 2.14 crore to support brand visibility and retail expansion.
Employee benefit expenses rose by 10.06% year-on-year to INR 17.62 crore, reflecting periodic wage increments and structural adjustments implemented in alignment with the new labour codes.
Other expenses expanded significantly by 32.58% year-on-year to INR 17.01 crore, driven by heightened operating overheads, selling expenses, and distribution scaling initiatives.
05 · Demand, customers & order book
Where demand is coming from
New personal care SKUs such as Comfy razors and Smoothe razors achieved distribution across approximately 70,000 retail outlets during the quarter.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Generated net sales of INR 57.26 crore in Q1 FY27 compared to INR 56.97 crore in Q1 FY26, delivering segment results of INR 9.87 crore.
Recorded net sales of INR 36.36 crore compared to INR 28.61 crore in Q1 FY26 (a 27.09% increase), though segment results showed a loss of INR 2.88 crore due to upfront marketing and capacity scaling costs.
Posted net sales of INR 8.64 crore compared to INR 7.76 crore in the year-ago period, with segment results reflecting a loss of INR 1.26 crore.
Geography and market mix
The company expanded its sales infrastructure and distribution reach, growing its stockist network by 7%, total outlet coverage by 17%, and effective outlet coverage by 8% during Q1 FY27.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The newly commissioned greenfield manufacturing plant in Telangana spans 10 acres with a 1.4 lakh sq. ft. built-up area, housing two fully automated high-speed production lines imported from Japan.
Projects, capex and execution
The Telangana manufacturing facility represents an aggregate capital investment of INR 150 crore, designed to establish future-ready domestic manufacturing capabilities under the Make in India initiative.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The company successfully scaled its presence in adjacent categories introduced in Q4 FY26, targeting annual revenues of INR 15 crore for razors and INR 10 crore for the Plastry wound care line.
09 · Reported developments
What changed operationally
The Comfy feminine hygiene brand sustained strong momentum with 21% gross sales growth, validating investments in manufacturing self-sufficiency and aggressive retail expansion.
New product introductions in razors and wound care achieved positive initial retailer acceptance and repeat orders, contributing 4% to total quarterly sales.
10 · Pressure points & risks
What is not going smoothly
Geopolitical conflicts in West Asia created cost pressures on raw and packing materials, compressing gross margins prior to price adjustments.
11 · Items worth noticing
The line items that can distort a quick read
The company recorded an exceptional item charge of INR 2.03 crore during Q1 FY27, representing additional statutory demand payments and arrears arising from the retrospective revision of lease rent for leasehold land by the Government of Tamil Nadu.
12 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
The company maintained a clean balance sheet with minimal finance costs of INR 0.04 crore, funding its capital expenditure programs primarily through internal accruals and accumulated reserves.
13 · Management guidance & targets
What management is targeting from here
Management expressed confidence that revenue and operating profits will achieve double-digit growth for the full financial year FY27, supported by the monetization of the new Comfy plant and the non-recurrence of previous year one-off charges.
14 · Beyond the numbers
What changed beyond the numbers
Reported update
HR Digitization and Training Initiatives
The company completed salary restructuring in compliance with new labour codes, rolled out digital HRMS modules via VIBE, and intensified field sales training programs for customer service executives.
Reported update
Statutory Auditor Review
Statutory auditors B S R & Co. LLP issued an unmodified limited review report on the standalone financial results for the quarter ended June 30, 2026.
15 · Previous-quarter changes
What changed since the previous quarter
Standalone revenue moderated from INR 149.77 crore in Q4 FY26 to INR 102.97 crore in Q1 FY27, reflecting seasonal demand patterns in core analgesic and healthcare product lines.
16 · Key Q&A
The quarter, answered directly
What does Amrutanjan Health Care do?
Amrutanjan Health Care Limited is a well-established Indian consumer health and wellness enterprise founded in 1893, operating primarily in the over-the-counter (OTC) pharmaceuticals, feminine hygiene, and healthy beverage segments.
What is the clearest takeaway from Q1 FY27?
Amrutanjan Health Care Limited recorded standalone revenue from operations of INR 102.97 crore for the quarter ended June 30, 2026 (Q1 FY27). Total income for the period stood at INR 106.78 crore, inclusive of other income amounting to INR 3.81 crore.
What drove revenue or demand?
Brand Comfy delivered strong gross sales growth of 21% year-on-year, led by a 43% surge in the Comfy XL variant and a 24% increase in 18-unit value packs, raising its revenue share to 33% of total company sales.
What mattered most for margins or profitability?
Management noted that raw and packing material costs remained elevated compared to Q1 FY26 due to supply chain disruptions stemming from the conflict in West Asia, partially offset by lower menthol crystal prices and targeted price increases.
What changed operationally beyond the headline numbers?
The newly commissioned greenfield manufacturing plant in Telangana spans 10 acres with a 1.4 lakh sq. ft. built-up area, housing two fully automated high-speed production lines imported from Japan.
What is management guiding or targeting from here?
Management expressed confidence that revenue and operating profits will achieve double-digit growth for the full financial year FY27, supported by the monetization of the new Comfy plant and the non-recurrence of previous year one-off charges.
17 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
18 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Comfy Plant Capacity Ramp-up: Monitor the operational utilization rates and profitability trajectory of the newly commissioned Telangana sanitary napkin facility.
- 02
Pain Category Demand Recovery: Track sequential volume growth in the flagship pain management portfolio and monitor whether analgesic pill market share gains plateau.
- 03
Input Cost Inflation Trajectory: Observe the impact of West Asian geopolitical tensions on raw material pricing and evaluate the effectiveness of company price hikes in protecting operating margins.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.